Sumatriptan Succinate Drug Asset Due Diligence Report 2026

This Sumatriptan Succinate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

114

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Sumatriptan Succinate can convert its Small molecule drug profile and 5-HT1B receptor x 5-HT1D receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Sumatriptan Succinate (query alias: sumatriptan)
Modality / target	Small molecule drug; 5-HT1B receptor x 5-HT1D receptor; 5-HT1B receptor agonists, 5-HT1D receptor agonists
Highest global status	Approved
Originator	GSK Plc
Active developers	Currax Pharmaceuticals LLC, GSK Plc, Simcere Pharmaceutical Group Ltd.

The MCP disease footprint includes Acute migraine, Cluster Headache, Migraine Disorders. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-UMIN000061371	Phase 4	参加者募集終了‐試験継続中/No longer recruiting	20	内服２時間後の頭痛改善、頭痛消失と有害事象
NCT06563375	Phase 1	Recruiting	35	Safety and Adverse Events (AEs)
NCT07515456	Not Applicable	Recruiting	75	Severity of headache

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase I, Open-Label, Two-Part Study of the Effect of Multiple-Dose Evobrutinib on Transporter Substrates Digoxin, Metformin, Rosuvastatin, and Sumatriptan Pharmacokinetics in Healthy Participants

Phase 1; n=40; evaluation: not stated. Reported fields: Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Digoxin(Geometric Mean) = 18.7 Hour*nanogram per milliliter (h*ng/mL) (Geometric Coefficient of Variation, 23.7); Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Digoxin(Geometric Mean): Ratio = 118.49(90% CI, 111.89 - 125.47); Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Digoxin(Geometric Mean): Ratio = 118.49(90% CI, 111.89 - 125.47)

Pilot study evaluating treatment with sumatriptan for moderate to severe post-traumatic headache: A phase 2 open-label study.

Phase 2; n=40; evaluation: Positive. Reported fields: Headache diary compliance rate = 80 %

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Phase 3; n=159; evaluation: not stated. Reported fields: Number of Participants Who Were Headache Pain Free at 120 Minutes After Treatment = 9 Participants ; Number of Participants Who Were Headache Pain Free at 120 Minutes After Treatment = 8 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Sumatriptan Succinate addresses Acute migraine, Cluster Headache, Migraine Disorders. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 7 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-06-30	Azurity Pharmaceuticals Expands Portfolio with CONTRAVE® and Related Assets	Approved	Financial terms not disclosed
2025-01-13	CNX Therapeutics expands European CNS portfolio with licensing agreement for Sumatriptan Alginate Film	Approved	US$0.8M upfront
2023-06-26	Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Sumatriptan succinate sustained release tablet and preparation method thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO